Cargando…

Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator

BACKGROUND: Navafenterol (AZD8871) is a dual-pharmacology muscarinic antagonist β(2−)agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary disease (COPD). The pharmacodynamics, safety and tolerability of single doses of navafenterol were investigated in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Dave, Balaguer, Victor, Astbury, Carol, Wählby-Hamrén, Ulrika, Jimenez, Eulalia, Seoane, Beatriz, Villarroel, Cristina, Lei, Alejhandra, Aggarwal, Ajay, Psallidas, Ioannis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487995/
https://www.ncbi.nlm.nih.gov/pubmed/32907566
http://dx.doi.org/10.1186/s12931-020-01347-7
_version_ 1783581602467545088
author Singh, Dave
Balaguer, Victor
Astbury, Carol
Wählby-Hamrén, Ulrika
Jimenez, Eulalia
Seoane, Beatriz
Villarroel, Cristina
Lei, Alejhandra
Aggarwal, Ajay
Psallidas, Ioannis
author_facet Singh, Dave
Balaguer, Victor
Astbury, Carol
Wählby-Hamrén, Ulrika
Jimenez, Eulalia
Seoane, Beatriz
Villarroel, Cristina
Lei, Alejhandra
Aggarwal, Ajay
Psallidas, Ioannis
author_sort Singh, Dave
collection PubMed
description BACKGROUND: Navafenterol (AZD8871) is a dual-pharmacology muscarinic antagonist β(2−)agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary disease (COPD). The pharmacodynamics, safety and tolerability of single doses of navafenterol were investigated in patients with moderate to severe COPD. METHODS: This was a randomized, five-way complete cross-over study. Patients received single doses of navafenterol 400 μg, navafenterol 1800 μg and placebo (all double-blind) and indacaterol 150 μg and tiotropium 18 μg (both open-label active comparators). The primary pharmacodynamic endpoint was change from baseline in trough forced expiratory volume in 1 s (FEV(1)) on day 2. Safety and tolerability were monitored throughout. RESULTS: Thirty-eight patients were randomized and 28 (73.7%) completed the study. Navafenterol 400 μg and 1800 μg demonstrated statistically significant improvements vs placebo in change from baseline in trough FEV(1) (least squares mean [95% confidence interval]: 0.111 [0.059, 0.163] L and 0.210 [0.156, 0.264] L, respectively, both P < .0001). The changes were significantly greater with navafenterol 1800 μg vs the active comparators (least squares mean treatment difference: 0.065–0.069 L, both P < .05). The frequency of treatment-emergent adverse events was similar for placebo and the active comparators (range 34.4–37.5%), slightly higher for navafenterol 400 μg (52.9%), and lowest for navafenterol 1800 μg (22.6%). CONCLUSIONS: Both doses of navafenterol demonstrated sustained bronchodilation over 24 h. Navafenterol was well tolerated and no safety concerns were raised. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02573155; URL: www.clinicaltrials.gov. Registered 9th October, 2015.
format Online
Article
Text
id pubmed-7487995
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74879952020-09-16 Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator Singh, Dave Balaguer, Victor Astbury, Carol Wählby-Hamrén, Ulrika Jimenez, Eulalia Seoane, Beatriz Villarroel, Cristina Lei, Alejhandra Aggarwal, Ajay Psallidas, Ioannis Respir Res Research BACKGROUND: Navafenterol (AZD8871) is a dual-pharmacology muscarinic antagonist β(2−)agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary disease (COPD). The pharmacodynamics, safety and tolerability of single doses of navafenterol were investigated in patients with moderate to severe COPD. METHODS: This was a randomized, five-way complete cross-over study. Patients received single doses of navafenterol 400 μg, navafenterol 1800 μg and placebo (all double-blind) and indacaterol 150 μg and tiotropium 18 μg (both open-label active comparators). The primary pharmacodynamic endpoint was change from baseline in trough forced expiratory volume in 1 s (FEV(1)) on day 2. Safety and tolerability were monitored throughout. RESULTS: Thirty-eight patients were randomized and 28 (73.7%) completed the study. Navafenterol 400 μg and 1800 μg demonstrated statistically significant improvements vs placebo in change from baseline in trough FEV(1) (least squares mean [95% confidence interval]: 0.111 [0.059, 0.163] L and 0.210 [0.156, 0.264] L, respectively, both P < .0001). The changes were significantly greater with navafenterol 1800 μg vs the active comparators (least squares mean treatment difference: 0.065–0.069 L, both P < .05). The frequency of treatment-emergent adverse events was similar for placebo and the active comparators (range 34.4–37.5%), slightly higher for navafenterol 400 μg (52.9%), and lowest for navafenterol 1800 μg (22.6%). CONCLUSIONS: Both doses of navafenterol demonstrated sustained bronchodilation over 24 h. Navafenterol was well tolerated and no safety concerns were raised. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02573155; URL: www.clinicaltrials.gov. Registered 9th October, 2015. BioMed Central 2020-09-09 2020 /pmc/articles/PMC7487995/ /pubmed/32907566 http://dx.doi.org/10.1186/s12931-020-01347-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Singh, Dave
Balaguer, Victor
Astbury, Carol
Wählby-Hamrén, Ulrika
Jimenez, Eulalia
Seoane, Beatriz
Villarroel, Cristina
Lei, Alejhandra
Aggarwal, Ajay
Psallidas, Ioannis
Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator
title Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator
title_full Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator
title_fullStr Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator
title_full_unstemmed Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator
title_short Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator
title_sort navafenterol (azd8871) in patients with copd: a randomized, double-blind, phase i study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487995/
https://www.ncbi.nlm.nih.gov/pubmed/32907566
http://dx.doi.org/10.1186/s12931-020-01347-7
work_keys_str_mv AT singhdave navafenterolazd8871inpatientswithcopdarandomizeddoubleblindphaseistudyevaluatingsafetyandpharmacodynamicsofsingledosesofthisnovelinhaledlongactingdualpharmacologybronchodilator
AT balaguervictor navafenterolazd8871inpatientswithcopdarandomizeddoubleblindphaseistudyevaluatingsafetyandpharmacodynamicsofsingledosesofthisnovelinhaledlongactingdualpharmacologybronchodilator
AT astburycarol navafenterolazd8871inpatientswithcopdarandomizeddoubleblindphaseistudyevaluatingsafetyandpharmacodynamicsofsingledosesofthisnovelinhaledlongactingdualpharmacologybronchodilator
AT wahlbyhamrenulrika navafenterolazd8871inpatientswithcopdarandomizeddoubleblindphaseistudyevaluatingsafetyandpharmacodynamicsofsingledosesofthisnovelinhaledlongactingdualpharmacologybronchodilator
AT jimenezeulalia navafenterolazd8871inpatientswithcopdarandomizeddoubleblindphaseistudyevaluatingsafetyandpharmacodynamicsofsingledosesofthisnovelinhaledlongactingdualpharmacologybronchodilator
AT seoanebeatriz navafenterolazd8871inpatientswithcopdarandomizeddoubleblindphaseistudyevaluatingsafetyandpharmacodynamicsofsingledosesofthisnovelinhaledlongactingdualpharmacologybronchodilator
AT villarroelcristina navafenterolazd8871inpatientswithcopdarandomizeddoubleblindphaseistudyevaluatingsafetyandpharmacodynamicsofsingledosesofthisnovelinhaledlongactingdualpharmacologybronchodilator
AT leialejhandra navafenterolazd8871inpatientswithcopdarandomizeddoubleblindphaseistudyevaluatingsafetyandpharmacodynamicsofsingledosesofthisnovelinhaledlongactingdualpharmacologybronchodilator
AT aggarwalajay navafenterolazd8871inpatientswithcopdarandomizeddoubleblindphaseistudyevaluatingsafetyandpharmacodynamicsofsingledosesofthisnovelinhaledlongactingdualpharmacologybronchodilator
AT psallidasioannis navafenterolazd8871inpatientswithcopdarandomizeddoubleblindphaseistudyevaluatingsafetyandpharmacodynamicsofsingledosesofthisnovelinhaledlongactingdualpharmacologybronchodilator